Compare Crispr Therapeutics AG (CRSP) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Wheaton Precious Metals Corp — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while Wheaton Precious Metals Corp trades at $138 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 11.7× Crispr Therapeutics AG's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WPM | |
|---|---|---|
Market Cap | $5.23B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $165.72 |
52-Week Low | $44.34 | $91.02 |
Enterprise Value | $3.65B | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wheaton Precious Metals (WPM) trades at $133.39, down 0.6% for the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.19, supported by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income reaching $1.47 billion, reflecting robust profitability margins.
The outlook remains positive with an 80% analyst buy rating and a $161.75 consensus price target, indicating ~21% upside. Key risks include reliance on commodity prices and projected negative cash flow in 2026. The stock's premium valuation (P/E 29.82) requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
